Web Results


Miglustat (OGT 918, N-butyl-deoxynojirimycin) is a drug developed by Oxford GlycoSciences and marketed by Actelion and is used primarily to treat type I ...


Miglustat is a drug used to treat Gaucher disease. ... Miglustat is now the first and only approved therapy for patients with Niemann-Pick disease type C (NP-C).


Miglustat, a small iminosugar, reversibly inhibits glucosylceramide synthase, which catalyses the first committed step of glycosphingolipid synthesis. Miglustat is ...


SC-48334 is a synthetic, N-alkylated imino analogue of D-glucose. Miglustat competitively and reversibly binds to and inhibits the activity of UDP-glucose ...


Apr 15, 2016 ... Miglustat: learn about side effects, dosage, special precautions, and more on MedlinePlus.


Zavesca (miglustat capsules, 100 mg) is an inhibitor of the enzyme glucosylceramide synthase, which is a glucosyl transferase enzyme responsible for the first ...


Feb 27, 2015 ... The results of this study suggest that miglustat treatment can improve or stabilize neurological manifestations, at least for a period of time; the ...


Miglustat is an inhibitor of glucosylceramide synthase that was launched as an oral treatment for mild to moderate type I Gaucher's disease in adult patients for ...


(miglustat capsules, 100mg) is an inhibitor of the enzyme glucosylceramide ... Miglustat, dosed at 50 and 100 mg in Gaucher patients, exhibits dose proportional.